Source: Orthopedic Design & Technology

Novadip: Novadip's Tissue Regeneration Product Used in First Pediatric Cases

Pivotal trial of NVD-003 is expected to begin in the second half of 2024.

Read full article »

Novadip's Competitors | Novadip's News | Novadip's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-Founder & CEO

Denis Dufrane

CEO Approval Rating

90/100

Novadip is a Belgium-based biopharmaceutical company that researches and commercializes tissue regeneration therapies for the treatment of cancer and orthopedic conditions.